不丧失专利新颖性的宽限期

2015-04-22 MedSci MedSci原创

一、建议,尽量避免使用不丧失新颖性的宽限期虽然专利法规定了不丧失专利新颖性的宽限期,但小编认为尽量不使用它,原因是:首先对符合规定的展览或会议要求较高,而且必须能出具证明才有效,同时此种公开对自己和他人的技术都会有影响,即公开日并非专利申请日,因此,建议,最好在展出或发表自己的技术之前,先申请专利,获得申请日和申请号之后,再参加展出或会议发表等,这样才能有效保证自己技术的新颖性。如果出于其他原因产

一、建议,尽量避免使用不丧失新颖性的宽限期


虽然专利法规定了不丧失专利新颖性的宽限期,但小编认为尽量不使用它,原因是:首先对符合规定的展览或会议要求较高,而且必须能出具证明才有效,同时此种公开对自己和他人的技术都会有影响,即公开日并非专利申请日,因此,建议,最好在展出或发表自己的技术之前,先申请专利,获得申请日和申请号之后,再参加展出或会议发表等,这样才能有效保证自己技术的新颖性。如果出于其他原因产生此种情况,请看如下的详解:

二、不丧失专利新颖性的宽限期

是指申请专利的发明创造在申请日(享有优先权的指优先权日)之前六个月内,有如下三种情况之一的公开,不丧失专利的新颖性。

2.1在中国政府主办或承认的国际展览会上首次展出的

中国政府主办的国际展览会,包括国务院、各部委主办或国务院批准由其他机关或地方政府举办的国际展览会。

中国政府承认的国际展览会,是指国际展览会公约规定的由国际展览局注册或认可的国际展览会。

申请人要求不丧失新颖性宽限期的,应自申请日起两个月内提交证明材料。

国际展览会的证明材料,应当由展览会主办单位出具。证明材料中应注明展览会展出日期、地点、展览会的名称以及该发明创造展出的日期、形式和内容,并加盖公章。

2.2在规定的学术会议或技术会议上首次发表的

规定的学术会议或技术会议,是指国务院有关主管部门或全国性学术团体组织召开的学术会议或技术会议,不包括省以下或受国务院各部委或全国性学术团体委托或以其名义组织召开的学术会议或技术会议。

学术会议和技术会议的证明材料,应由国务院有关主管部门或组织会议的全国性学术团体出具。证明材料中应注明会议召开的日期、地点、会议的名称以及该发明创造发表的日期、形式和内容,并加盖公章。

2.3他人未经申请人同意而泄露其内容的

包括他人未遵守明示或默示的保密信约而将发明创造的内容公开,也包括他人用威胁、欺诈或间谍活动等手段从发明人或申请人那里得知发明创造的内容而后造成的公开。
关于他人泄露申请内容的证明材料,应当注明泄露日期、泄露方式、泄露的内容,并由证明人签字或盖章。

三、“不丧失专利新颖性公开”注意的问题

3.1时间的限制

公开后六个月内,提出专利申请的同时提出不丧失新颖性的宽限期,才有效;超过六个月,即不存在宽限期的意义。

3.2公开者的身份要求

应该是申请人(包括发明人),即是专利的所有者自己的公开,才有资格提出不丧失新颖性的宽限期。

公开的主体必须和后来申请专利的主体是一致的。公开的法人或个人,应当是后来的专利申请人;公开的是个人,此个人是发明人,而专利申请是职务发明,也可享受宽限期。

泄露人不能是申请人本人,但可以是申请人单位的工作人员,包括发明人和设计人,也可以是任何第三人,包括从申请人那里直接或间接获得发明创造内容的人。

3.3宽限期的效力

宽限期是这种公开在一定期限内对申请人的专利申请不视为影响其新颖性和创造性的现有技术,并不是把发明创造的公开日看作是专利申请的申请日。

从公开之日至提出申请期间,如果第三人独立地作出了同样的发明创造,而且在申请人提出专利申请以前提出了专利申请,那么,根据先申请原则,申请人就不能取得专利权。当然,由于申请人(包括发明人)的公开,使该发明创造成为现有技术,所以,第三人的申请也没有新颖性,也不能取得专利权。

宽限期仅仅是在不可避免或者无意识地公开发明创造的情况下,专利法给予的一个补救措施,其保护是有限的。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=56248, encodeId=f63e562489d, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56249, encodeId=6253562495f, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56250, encodeId=324456250c7, content=继续关注,, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56251, encodeId=a8fa5625161, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56252, encodeId=a4e856252a1, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56253, encodeId=f25d5625309, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    不错的建议……

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=56248, encodeId=f63e562489d, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56249, encodeId=6253562495f, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56250, encodeId=324456250c7, content=继续关注,, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56251, encodeId=a8fa5625161, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56252, encodeId=a4e856252a1, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56253, encodeId=f25d5625309, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    不错的建议……

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=56248, encodeId=f63e562489d, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56249, encodeId=6253562495f, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56250, encodeId=324456250c7, content=继续关注,, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56251, encodeId=a8fa5625161, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56252, encodeId=a4e856252a1, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56253, encodeId=f25d5625309, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    继续关注,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=56248, encodeId=f63e562489d, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56249, encodeId=6253562495f, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56250, encodeId=324456250c7, content=继续关注,, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56251, encodeId=a8fa5625161, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56252, encodeId=a4e856252a1, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56253, encodeId=f25d5625309, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=56248, encodeId=f63e562489d, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56249, encodeId=6253562495f, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56250, encodeId=324456250c7, content=继续关注,, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56251, encodeId=a8fa5625161, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56252, encodeId=a4e856252a1, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56253, encodeId=f25d5625309, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=56248, encodeId=f63e562489d, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56249, encodeId=6253562495f, content=不错的建议……, beContent=null, objectType=article, channel=null, level=null, likeNumber=180, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56250, encodeId=324456250c7, content=继续关注,, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56251, encodeId=a8fa5625161, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56252, encodeId=a4e856252a1, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56253, encodeId=f25d5625309, content=感谢分享~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 11:25:00 CST 2016, time=2016-01-12, status=1, ipAttribution=)]
    2016-01-12 medsic

    感谢分享~~

    0

相关资讯

知识产权将从“云端”走向大众

原标题:知识产权将从“云端”走向大众 知识产权不再是曲高和寡,而将成为人人都要了解的一项技能。昨天举行的上海市知识产权联席会议部署了2015年知识产权工作,其中全力以赴做好市委关于加快建设具有全球影响力的科技创新中心成为重中之重。上海市副市长赵雯表示,知识产权是创新的保障,在全面提倡“大众创业、万众创新”的今天,知识产权将从“云端”走向大众。 尽管本市去年专利申请总量同比下降5.5%,但4

在线课堂:科研工作与知识产权保护系列课程

知识产权也称其为“知识财产权”,是关于人类在社会实践中创造的智力劳动成果的专有权利,是一种无形财产权。它有两类:一类是著作权,也称为版权,另一类是工业产权,也称为产业产权,其中产业产权又主要包括专利权与商标权。知识产权保护是非常重要的。 本系列课程涵盖目前国家非常重视的知识产权领域中的专利问题,课程中江编辑将为大家细致的讲解科研工作者关于认知专利、运用专利等方面的知识,尤其涉及医学、药学以及

如何看懂—专利文献号

(一)专利文献号专利文献是指国家知识产权局按照法定程序公布的专利申请文件和公告的授权专利文件。专利文献种类是指国家知识产权局按照相关法律法规对发明、实用新型、外观设计专利申请在法定程序中予以公布或公告,由此产生的各种专利文献。专利文献号是指国家知识产权局按照法定程序,在专利申请公布和专利授权公告时给予的专利文献标识号码。特点一件专利申请形成的专利文献至始至终只能获得一个专利文献号;例如:发明专利申

专利申请的十一大误区

随着近几年国家对知识产权的重视,国内的企业对专利在提升核心竞争力方面的作用有了进一步的认识,纷纷加强了专利工作,专利申请量大幅度增加,但是在专利代理过程中,笔者发现不少企业在专利申请过程中,仍存在误区,需要早日改进。误区一:自主研发的成果不申请专利就有知识产权。一些技术人员认为只要是自主创新,就有了自主知识产权。其实不然,专利是一种垄断权,自主研发的技术成果如果不申请专利,就得不到法律确认和保

医药生物领域--不能申请专利的情形

一、疾病的诊断和治疗方法 是指以有生命的人体或动物体为直接实施对象,进行识别、确定或消除病因或病灶的过程。 出于人道主义的考虑和社会伦理的原因,医生在诊断和治疗过程中应当有选择各种方法和条件的自由; 另外,这类方法直接以有生命的人体或动物体为实施对象,无法在产业上利用,不属于专利法意义上的发明创造,因此,疾病的诊断和治疗方法不能被授予专利权。 例如: 1.外科手术

案例介绍—医药生物领域的授权专利

1、用于实施疾病诊断和治疗方法的仪器或装置例如:诊断和治疗用的仪器设备或手术器械。案例:一种重叠覆盖椭球体的消融灶产生系统及方法(授权公告号 CN 100484491 C)一种治疗肛瘘的压力控制单向挂线器(授权公告号 CN 100581488 C)医用封堵器抗压能力测试装置(授权公告号 CN 102435501 B)一种多功能医用洗头装置(授权公告号 CN 203263699 U)一种手术撑开